- Home
- YMAT vs BIVI Comparison
YMAT vs BIVI Comparison
Compare YMAT & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMAT | BIVI |
|---|---|---|
| Founded | 1970 | 2013 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | YMAT | BIVI |
|---|---|---|
| Price | $0.26 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 60.4K | 53.6K |
| Earning Date | 05-09-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.82 |
| 52 Week High | $6.45 | $9.09 |
Technical Indicators
Market Signals| Indicator | YMAT | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 33.68 | 61.16 |
| Support Level | N/A | $1.52 |
| Resistance Level | $0.35 | $1.68 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 5.33 | 88.68 |
Price Performance
Historical ComparisonAbout YMAT J-Star Holding Co. Ltd. Ordinary Shares
J Star Holding Co Ltd is engaged in the research, development and manufacturing of carbon fiber for a wide variety of products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.